In mouse models, the systemic administration of MYXV demonstrated efficacy in eliminating MM cells by inducing robust CD8+ T antitumor immune responses, suggesting the possibility of its use as a systemic therapy in patients (101). Here, CD8A is linked to Miyoshi myopathy.